BRPI0921469A2 - proteínas de ligação que inibem a interação com o receptor de vegf-a - Google Patents
proteínas de ligação que inibem a interação com o receptor de vegf-aInfo
- Publication number
- BRPI0921469A2 BRPI0921469A2 BRPI0921469A BRPI0921469A BRPI0921469A2 BR PI0921469 A2 BRPI0921469 A2 BR PI0921469A2 BR PI0921469 A BRPI0921469 A BR PI0921469A BR PI0921469 A BRPI0921469 A BR PI0921469A BR PI0921469 A2 BRPI0921469 A2 BR PI0921469A2
- Authority
- BR
- Brazil
- Prior art keywords
- vegf
- receptor
- binding proteins
- inhibit interaction
- inhibit
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 title 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08168166.0 | 2008-11-03 | ||
EP08168166 | 2008-11-03 | ||
PCT/EP2009/064483 WO2010060748A1 (en) | 2008-11-03 | 2009-11-03 | Binding proteins inhibiting the vegf-a receptor interaction |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0921469A2 true BRPI0921469A2 (pt) | 2016-01-12 |
BRPI0921469B1 BRPI0921469B1 (pt) | 2022-01-18 |
Family
ID=40149742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921469-0A BRPI0921469B1 (pt) | 2008-11-03 | 2009-11-03 | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
Country Status (15)
Country | Link |
---|---|
US (2) | US8901076B2 (pt) |
EP (2) | EP2358746B1 (pt) |
JP (2) | JP5954990B2 (pt) |
KR (1) | KR101698362B1 (pt) |
CN (2) | CN107011425B (pt) |
AU (1) | AU2009319204B2 (pt) |
BR (1) | BRPI0921469B1 (pt) |
CA (1) | CA2742241C (pt) |
DK (1) | DK2358746T3 (pt) |
ES (1) | ES2836948T3 (pt) |
IL (1) | IL212589A (pt) |
MX (2) | MX359570B (pt) |
NZ (1) | NZ592591A (pt) |
RU (2) | RU2650765C1 (pt) |
WO (1) | WO2010060748A1 (pt) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
KR101482483B1 (ko) | 2006-04-07 | 2015-01-15 | 에르피오 세러퓨틱스 인코포레이티드 | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 |
AU2014243418B2 (en) * | 2010-04-30 | 2016-09-22 | Molecular Partners Ag | Modified binding proteins inhibiting the VEGF-A receptor interaction |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
CN113278077A (zh) * | 2010-11-26 | 2021-08-20 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
JP2014519808A (ja) | 2011-04-29 | 2014-08-21 | ヤンセン バイオテツク,インコーポレーテツド | Il4/il13に結合する反復タンパク質及び使用 |
WO2012172054A1 (en) | 2011-06-16 | 2012-12-20 | Scil Proteins Gmbh | Modified multimeric ubiquitin proteins binding vegf-a |
PT2780371T (pt) | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica |
AU2012338731B2 (en) | 2011-11-16 | 2017-07-06 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
PT2594587E (pt) | 2011-11-16 | 2014-08-27 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para diminuir o risco de mortalidade num paciente com uma doença aguda ou crónica ou num estado agudo |
CN118105479A (zh) | 2011-11-16 | 2024-05-31 | 艾德里诺医药公司 | 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架 |
US9535060B2 (en) | 2011-11-16 | 2017-01-03 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
CA2856142A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
EP3646880A1 (en) | 2012-05-07 | 2020-05-06 | Allergan, Inc. | Method of treating amd in patients refractory to anti-vegf therapy |
SG11201408196RA (en) * | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
AU2012101678B4 (en) * | 2012-07-03 | 2013-01-24 | Novartis Ag | Use of device |
JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
JP2015528454A (ja) * | 2012-08-28 | 2015-09-28 | ノバルティス アーゲー | 眼血管増殖性疾患の処置におけるvegfアンタゴニストの使用 |
EP2904403B1 (en) | 2012-10-02 | 2018-03-28 | SphingoTec GmbH | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
CN107991501A (zh) | 2013-01-08 | 2018-05-04 | 斯弗因高泰克有限公司 | 生长激素的禁食水平作为心血管风险的预测标志物 |
EP2961773B1 (en) * | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
BR112015021000A2 (pt) * | 2013-03-14 | 2017-07-18 | Allergan Inc | composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação |
RU2673455C2 (ru) | 2013-03-20 | 2018-11-27 | Сфинготек Гмбх | Адреномедуллин для направленной терапии по снижению кровяного давления |
FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
JP6486908B2 (ja) | 2013-05-31 | 2019-03-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 |
WO2014203181A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Treatment of polypoidal choroidal vasculopathy |
EP3010526A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
US20160137717A1 (en) | 2013-06-20 | 2016-05-19 | Gabriela Burian | Use of a vegf antagonist in treating choroidal neovascularisation |
AU2014288847A1 (en) * | 2013-07-11 | 2016-01-28 | Novartis Ag | Use of a VEGF antagonist in treating retinopathy of prematurity |
MX2016000384A (es) | 2013-07-11 | 2016-04-29 | Novartis Ag | Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. |
SG10201912985RA (en) | 2013-07-12 | 2020-02-27 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions |
KR20160070164A (ko) * | 2013-11-05 | 2016-06-17 | 알러간, 인코포레이티드 | 항-vegf darpin으로 눈의 병태를 치료하는 방법 |
CA2947456C (en) | 2014-05-12 | 2023-03-14 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
US20160097781A1 (en) | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
EP3277711B9 (en) * | 2015-04-02 | 2023-08-16 | Molecular Partners AG | Designed ankyrin repeat domains with binding specificity for serum albumin |
RU2733471C2 (ru) | 2015-04-24 | 2020-10-01 | Сфинготек Гмбх | Способ прогнозирования риска развития хронического заболевания почек |
TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
BR112018009951A8 (pt) | 2015-11-18 | 2019-02-26 | Sio2 Medical Products Inc | fármaco oftálmico |
BR112018010005A2 (pt) | 2015-11-18 | 2018-11-21 | Formycon Ag | seringa pré-carregada, e, kit |
RU2734958C2 (ru) | 2015-11-18 | 2020-10-26 | Формикон Аг | Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf |
EP3407868A1 (en) | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
WO2017148904A1 (en) | 2016-02-29 | 2017-09-08 | Franz Grus | Predictive markers useful in the treatment of wet age-related macular degeneration |
CH713803B1 (de) | 2016-04-21 | 2023-08-15 | 4TEEN4 Pharmaceuticals GmbH | Verfahren zur Diagnose durch Bestimmung von DPP3, Hemmer der Aktivität von DPP3 und Zusammensetzung mit einem Hemmer. |
MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
WO2018007588A1 (en) | 2016-07-08 | 2018-01-11 | Sphingotec Gmbh | Adrenomedullin for assessing congestion in a subject with acute heart failure |
SG10201912556VA (en) | 2016-07-20 | 2020-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
NZ751689A (en) | 2016-09-22 | 2021-07-30 | Molecular Partners Ag | Recombinant binding proteins and their use |
EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
CN110167962B (zh) | 2016-12-16 | 2024-06-07 | 艾德里诺医药公司 | 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
WO2018217995A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
CA3063995A1 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
BR112019024966A2 (pt) | 2017-05-30 | 2020-06-23 | Sphingotec Gmbh | Método para diagnosticar ou monitorar a função renal ou diagnosticar a disfunção renal |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
EP3668976A1 (en) * | 2017-08-18 | 2020-06-24 | Cambridge Enterprise Limited | Modular binding proteins |
EP4159229A1 (en) | 2017-09-25 | 2023-04-05 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
BR112020005682A2 (pt) | 2017-10-18 | 2020-10-20 | Adrenomed Ag | monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm) |
CN111542755A (zh) | 2017-10-24 | 2020-08-14 | 思芬构技术有限公司 | 用于预测第一次心血管事件的硒蛋白p |
US11530276B2 (en) | 2017-10-25 | 2022-12-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
BR112020014940A2 (pt) | 2018-02-08 | 2020-12-08 | Sphingotec Gmbh | Adrenomedulina (adm) para diagnóstico e/ou predição de demência e ligante antiadrenomedulina para uso em terapia e prevenção de demência |
EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
BR112021010069A2 (pt) | 2018-12-20 | 2021-11-23 | Sphingotec Gmbh | Selenoproteína p em insuficiência cardíaca |
CN113557031A (zh) | 2018-12-21 | 2021-10-26 | 4Teen4制药有限公司 | 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测 |
AU2020289080A1 (en) | 2019-06-04 | 2021-12-23 | Molecular Partners Ag | Multispecific proteins |
CN114364984A (zh) | 2019-08-15 | 2022-04-15 | 思芬构技术有限公司 | 一种诊断或监测儿科患者的肾功能或诊断肾功能障碍的方法 |
US20220307065A1 (en) | 2019-08-30 | 2022-09-29 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
CN115003689A (zh) | 2019-12-11 | 2022-09-02 | 分子合作伙伴股份公司 | 具有改变的表面残基的经设计的锚蛋白重复结构域 |
EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
KR20220145897A (ko) | 2020-02-27 | 2022-10-31 | 아드레노메드 아게 | 쇼크의 치료 또는 예방에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드 |
CN115244401A (zh) | 2020-02-27 | 2022-10-25 | 4Teen4制药有限公司 | 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3 |
KR20220145898A (ko) | 2020-02-27 | 2022-10-31 | 아드레노메드 아게 | 쇼크 환자의 치료에 사용하기 위한 항-아드레노메둘린 (adm) 결합제 |
EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
BR112022017277A2 (pt) | 2020-03-16 | 2022-10-18 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 em pacientes infectados com coronavírus |
AU2021238592A1 (en) | 2020-03-16 | 2022-11-03 | Sphingotec Gmbh | Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against Adrenomedullin |
CR20220618A (es) | 2020-05-06 | 2023-01-19 | Molecular Partners Ag | Nuevas proteinas de unión a repeticiones de anquirina y sus usos |
JP2023528204A (ja) | 2020-05-14 | 2023-07-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
AU2021403833A1 (en) | 2020-12-16 | 2023-07-27 | Molecular Partners Ag | Novel slow-release prodrugs |
BR112023018293A2 (pt) | 2021-03-09 | 2023-10-31 | Molecular Partners Ag | Acopladores de célula t multiespecíficos à base de darpin |
JP2024509241A (ja) | 2021-03-09 | 2024-02-29 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規のDARPinに基づくCD123エンゲージャ |
AU2022231913A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd33 engagers |
EP4305063A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Protease cleavable prodrugs |
WO2022263648A1 (en) | 2021-06-18 | 2022-12-22 | Sphingotec Gmbh | A method for predicting sepsis and septic shock |
KR20240041912A (ko) | 2021-06-29 | 2024-04-01 | 베리솔 게엠베하 | 체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커 |
EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
CA3239407A1 (en) | 2021-12-14 | 2023-06-22 | Simon FONTAINE | Designed repeat domains with dual binding specificity and their use |
WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
US20240132546A1 (en) | 2022-07-31 | 2024-04-25 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
WO2024059686A2 (en) * | 2022-09-15 | 2024-03-21 | The Regents Of The University Of California | Darpin backbones and rigidified electron microscopy imaging scaffolds |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
DE69841815D1 (de) | 1997-04-07 | 2010-09-16 | Genentech Inc | Anti-VEGF Antikörper |
SI1325932T1 (pt) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
WO1998048008A1 (en) | 1997-04-23 | 1998-10-29 | Plueckthun Andreas | Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules |
WO2000032823A1 (en) | 1998-12-02 | 2000-06-08 | Phylos, Inc. | Dna-protein fusions and uses thereof |
US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
CA2376379C (en) | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
RU2299208C2 (ru) * | 2001-05-08 | 2007-05-20 | Шеринг Акциенгезельшафт | Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3 |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1711196A4 (en) * | 2003-12-05 | 2011-09-14 | Bristol Myers Squibb Co | INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS |
EA013615B1 (ru) * | 2004-11-12 | 2010-06-30 | Байер Шеринг Фарма Акциенгезельшафт | Рекомбинантный онколитический парамиксовирус и его применение |
CA2995971A1 (en) * | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
RU2412249C2 (ru) | 2005-07-08 | 2011-02-20 | Юниверсити Оф Цюрих | Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов |
EP2727936B1 (en) * | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
JP2010518013A (ja) * | 2007-02-01 | 2010-05-27 | ジェネンテック, インコーポレイテッド | 血管形成阻害剤を含む組み合わせ治療の方法 |
US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
-
2009
- 2009-11-03 KR KR1020117009012A patent/KR101698362B1/ko active IP Right Grant
- 2009-11-03 JP JP2011533752A patent/JP5954990B2/ja active Active
- 2009-11-03 BR BRPI0921469-0A patent/BRPI0921469B1/pt active IP Right Grant
- 2009-11-03 US US13/126,821 patent/US8901076B2/en active Active
- 2009-11-03 EP EP09756279.7A patent/EP2358746B1/en active Active
- 2009-11-03 CN CN201710092752.9A patent/CN107011425B/zh active Active
- 2009-11-03 CN CN2009801536047A patent/CN102272148A/zh active Pending
- 2009-11-03 RU RU2015108838A patent/RU2650765C1/ru active
- 2009-11-03 ES ES09756279T patent/ES2836948T3/es active Active
- 2009-11-03 MX MX2015010520A patent/MX359570B/es unknown
- 2009-11-03 NZ NZ592591A patent/NZ592591A/en unknown
- 2009-11-03 MX MX2011004649A patent/MX2011004649A/es unknown
- 2009-11-03 EP EP20196328.7A patent/EP3785735A1/en not_active Withdrawn
- 2009-11-03 CA CA2742241A patent/CA2742241C/en active Active
- 2009-11-03 WO PCT/EP2009/064483 patent/WO2010060748A1/en active Application Filing
- 2009-11-03 DK DK09756279.7T patent/DK2358746T3/da active
- 2009-11-03 RU RU2011122201/10A patent/RU2550258C2/ru active
- 2009-11-03 AU AU2009319204A patent/AU2009319204B2/en active Active
-
2011
- 2011-04-28 IL IL212589A patent/IL212589A/en active IP Right Grant
-
2014
- 2014-10-28 US US14/525,553 patent/US20150344539A1/en not_active Abandoned
-
2015
- 2015-03-17 JP JP2015053249A patent/JP6329503B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN102272148A (zh) | 2011-12-07 |
JP2015133978A (ja) | 2015-07-27 |
IL212589A0 (en) | 2011-07-31 |
US20150344539A1 (en) | 2015-12-03 |
US8901076B2 (en) | 2014-12-02 |
BRPI0921469B1 (pt) | 2022-01-18 |
NZ592591A (en) | 2012-04-27 |
MX359570B (es) | 2018-10-01 |
JP5954990B2 (ja) | 2016-07-20 |
CN107011425A (zh) | 2017-08-04 |
KR101698362B1 (ko) | 2017-01-20 |
CN107011425B (zh) | 2021-01-01 |
CA2742241A1 (en) | 2010-06-03 |
US20110207668A1 (en) | 2011-08-25 |
ES2836948T3 (es) | 2021-06-28 |
RU2650765C1 (ru) | 2018-04-17 |
EP2358746B1 (en) | 2020-09-16 |
JP6329503B2 (ja) | 2018-05-23 |
AU2009319204B2 (en) | 2014-11-13 |
DK2358746T3 (da) | 2020-12-21 |
AU2009319204A1 (en) | 2010-06-03 |
RU2550258C2 (ru) | 2015-05-10 |
EP3785735A1 (en) | 2021-03-03 |
JP2012507271A (ja) | 2012-03-29 |
EP2358746A1 (en) | 2011-08-24 |
WO2010060748A1 (en) | 2010-06-03 |
MX2011004649A (es) | 2011-05-30 |
KR20110082528A (ko) | 2011-07-19 |
IL212589A (en) | 2017-01-31 |
RU2011122201A (ru) | 2012-12-10 |
CA2742241C (en) | 2019-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0921469A2 (pt) | proteínas de ligação que inibem a interação com o receptor de vegf-a | |
CY2019004I1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
BRPI0922505A2 (pt) | proteínas de ligação a receptor cgrp humano | |
IS8842A (is) | Kjarnviðtaka bindimiðlar. | |
IL222749A0 (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
NO20072812L (no) | Forbedret oreenhet | |
ATE509022T1 (de) | Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide | |
BRPI0720699A2 (pt) | Programas ligados | |
NO20074696L (no) | Aktiveringsmekanisme | |
BRPI0910835A2 (pt) | conjunto com pílulas hemostáticas e radiograficamente detectáveis | |
DE602008004276D1 (de) | Luftkanone | |
BRPI0913515A2 (pt) | fechamento com mecanismo limitador | |
BRPI0919024A2 (pt) | compostos que seletivamente modulam o receptor cb2 | |
SE0850135L (sv) | Häftapparat | |
BRPI0909289A2 (pt) | Mistura simbiótica | |
BRPI0913513A2 (pt) | fechamento com mecanismo limitador | |
ATE539819T1 (de) | Elektronisch gesteuertes zapfenbelastungssystem | |
BRPI0812991A2 (pt) | Utilização de combustível melhorado | |
DK2126380T3 (da) | Rillet befæstigelseselement | |
DE602008005825D1 (de) | Luftdruckwaffe | |
BRPI0914557A2 (pt) | proteína de ligação de biotina modificada | |
FI20080585A (fi) | Telkimekanismi | |
DE602007008589D1 (de) | Pyridooxazepin-progesteronrezeptor-modulatoren | |
BRPI0817449A2 (pt) | Composição de combustível | |
DE112008001259A5 (de) | Dosiermagnet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |